With liver ailments on the rise, and obesity a key driver, understanding the treatment options available is critical.

Arrowhead Pharmaceuticals, Inc. today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be ...

In 2025, a new breed of entrepreneurial disruptors is set to reshape industries and redefine success on their own term ...

Fabric, a leader in care delivery and consumer experience, today announced major updates to its Virtual Care platform, including the launch of a subscription-based care model that brings ...

College basketball stars Olivia Miles and Ta'Niyah Latson made decisions this week, as the NCAA transfer portal continues ...

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

Every patient in the trial has met the primary safety endpoint, confirmed through PET imaging showing precise retention of the therapeutic Yttrium-90 isotope at the injection site—with no observed ...

Daily treatment with IPL344 for up to three years was safe and slowed ALS progression in a small Phase 2a clinical trial, ...

Frexalimab was well tolerated and maintained disease control over two years in adults with relapsing MS in an open-label ...

UD students interested in advanced health care professions will have an additional pathway, starting with the entering undergraduate class in fall 2025. UD’s Doctor of Physical Therapy and Master of ...

“Most DNP programs require you to have a master’s degree with some element of clinical experience to be able to develop a DNP ...

Neurosense Therapeutics’ PrimeC significantly reduces blood levels of miRNAs linked to amyotrophic lateral sclerosis, trial data showed.